Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Latest News — Page 18

Jascayd EU IPF approval

Clinical Practice

Jascayd EU IPF Approval Establishes New Fibrosis Option

🧬 What could Jascayd’s EU approval mean for Idiopathic Pulmonary Fibrosis care?

The new authorization introduces a fresh treatment option for fibrosis, strengthening options for patients and clinicians across Europe.

Read the full breakdown of this regulatory milestone.
#SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

Syenza TeamRead ›
Novartis Q2 Sales Growth

Biologics And Biosimilars

Novartis Q2 Sales Growth Rebounds via New Launches

What’s powering Novartis’s Q2 sales rebound?

The pharma leader has posted renewed growth, fueled by strong momentum from its latest product launches across key portfolios. These results highlight the company’s strategic focus on innovation and pipeline delivery.

Read the full breakdown on Syenza.

#SyenzaNews #pharmaceuticals #biotech #innovation #MarketAccess

Syenza TeamRead ›
Brazil pharmaceutical supply chain vulnerabilities

Big Data Analysis

Brazil pharmaceutical supply chain vulnerabilities exposed by pandemic disruptions

🔍 How did the pandemic expose critical weaknesses in Brazil’s pharmaceutical supply chain?

From raw-material dependencies to distribution bottlenecks, COVID-19 disruptions laid bare vulnerabilities that continue to threaten medicine availability and market access across the region.

Read the full analysis to see what these lessons mean for building more resilient supply systems.
#SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #healthcarepolicy

Syenza TeamRead ›
LLM Judges Clinical Evaluation Limits

Artificial Intelligence And Machine Learning

LLM Judges Clinical Evaluation Limits in Multilingual Health Settings

Are LLMs truly reliable judges for clinical evaluations in multilingual settings?

New research highlights critical limitations when using large language models to assess healthcare quality across languages, from biased outputs to gaps in cultural context. These findings underscore the need for human oversight in global health applications.

Read the full analysis to see what it means for responsible AI adoption in healthcare.
#SyenzaNews #AIinHealthcare #digitalhealth #ai #innovation

Syenza TeamRead ›
Gilead GÉNESE Portugal grants

Clinical Practice

Gilead GÉNESE Portugal grants advancing oncology evidence

🚀 How are Gilead and GNese Portugal accelerating oncology evidence?

Through targeted grants, the partnership is strengthening real-world data generation and clinical insights to advance cancer care across Portugal.

Explore how this initiative is shaping the future of oncology research.
#SyenzaNews #oncology #pharmaceuticals #innovation

Syenza TeamRead ›
Pembrolizumab dMMR Endometrial Cancer PFS

Clinical Practice

Pembrolizumab dMMR Endometrial Cancer PFS Benefit Confirmed in KEYNOTE-C93 Trial

🔬 Can immunotherapy redefine outcomes in endometrial cancer?

New data confirms pembrolizumab delivers a significant progression-free survival benefit for patients with dMMR endometrial cancer, strengthening its role in precision oncology and targeted treatment strategies.

Read the full analysis to see how these findings could reshape clinical practice.
#SyenzaNews #oncology #precisionmedicine #innovation

Syenza TeamRead ›
EU Oral Semaglutide Approval

Clinical Practice

EU Oral Semaglutide Approval Boosts Weight Management Options

✨ How is oral semaglutide reshaping weight management across Europe?

The EU approval of oral semaglutide expands patient options with a convenient, evidence-based therapy that supports broader access to effective obesity care. This milestone strengthens pharmaceutical innovation while addressing growing demand for non-injectable treatments.

Discover the full impact on market access and patient outcomes.
#SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

Syenza TeamRead ›
Portugal AI Health Governance

Artificial Intelligence And Machine Learning

Portugal AI Health Governance Pioneers Global Standards

🚀 How is Portugal pioneering global standards in AI health governance?

By developing forward-thinking regulatory frameworks and ethical guidelines, the country is ensuring responsible AI adoption across healthcare systems while fostering innovation and trust.

Discover how these efforts are shaping the future of digital health worldwide.
#SyenzaNews #AIinHealthcare #digitalhealth #governance #innovation

Syenza TeamRead ›
NICE Finerenone HFpEF Approval

Cardiovascular And Metabolic Diseases

NICE Finerenone HFpEF Approval Advances HFpEF Therapy Options

How is NICE expanding treatment options for HFpEF patients?

The UK’s National Institute for Health and Care Excellence has approved finerenone, giving clinicians a new evidence-based therapy to improve outcomes in heart failure with preserved ejection fraction. This milestone broadens the therapeutic landscape and reinforces the value of targeted drug development.

Read the full analysis.
#SyenzaNews #pharmaceuticals #HealthcareInnovation #innovation #MarketAccess

Syenza TeamRead ›
Generic Semaglutide South Africa

Clinical Practice

Generic Semaglutide South Africa Approved Post Patent Expiration

💊 What does South Africa’s approval of generic semaglutide mean for patients and payers?

Following patent expiration, the green light for generic versions promises lower costs and wider access to this key treatment for type 2 diabetes and weight management.

Explore how this decision could reshape market access and affordability across emerging economies.
#SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #costeffectiveness

Syenza TeamRead ›
FDA gedatolisib fulvestrant approval breast cancer artwork

Clinical Practice

FDA gedatolisib fulvestrant approval offers new hope in breast cancer

Exciting FDA approval! Gedatolisib plus fulvestrant delivers strong PFS benefits (HRs 0.24 & 0.33) for HR+/HER2- breast cancer patients, offering meaningful new hope. Read the full Syenza News article to explore the data. #FDAapproval #BreastCancer #Oncology #ClinicalTrials #Healthcare

Syenza TeamRead ›
Digital Medical Device Regulations

Asia

Digital Medical Device Regulations Enable Rapid Approvals

🚀 What if smarter regulations could fast-track digital medical device approvals?

Recent updates are streamlining pathways for MedTech innovators, cutting timelines while maintaining rigorous safety standards. This shift is accelerating patient access to next-generation health technologies.

Read the full analysis to see what it means for your pipeline.
#SyenzaNews #medicaldevices #regulatoryaffairs #innovation #DigitalTransformation

Syenza TeamRead ›
Celltrion Q2 Biosimilar Growth

Asia

Celltrion Q2 Biosimilar Growth Fuels Margin Expansion

📈 How is Celltrion turning biosimilar momentum into stronger margins?

The company’s Q2 results highlight robust growth across its biosimilar portfolio, driving improved profitability and reinforcing its competitive edge in global markets.

Discover the full financial breakdown and strategic implications.
#SyenzaNews #biotechnology #pharmaceuticals #innovation #MarketAccess

Syenza TeamRead ›
tablet manufacturing capacity expansion

Europe

Tablet manufacturing capacity expansion enhances supply resilience

How is expanding tablet manufacturing capacity reshaping pharma supply resilience?

Recent capacity boosts are helping manufacturers meet rising demand while reducing disruption risks across global medication flows. This move strengthens continuity for patients and providers alike.

Discover the strategic details behind the expansion.
#SyenzaNews #pharmaceuticals #drugdevelopment #innovation #strategicplanning

Syenza TeamRead ›
EIT Health 2027 Grants

Artificial Intelligence And Machine Learning

EIT Health 2027 Grants Key Provisions and Implications

What opportunities do EIT Health’s 2027 grants unlock for Europe’s health innovators?

New provisions prioritize cross-border collaboration, sustainability, and digital solutions, with major implications for startups, researchers, and health systems seeking funding.

Explore how these changes could shape your next project.
#SyenzaNews #HealthcareInnovation #HealthTech #innovation

Syenza TeamRead ›
Health economics policy debate illustration

Health Equity And Access To Care

US health economics policy challenges Explained by Experts

🧐 Why does the US spend 17.5% of GDP on health yet leave coverage so unequal?

Adverse selection and asymmetric information distort markets. The “three-legged stool” of reforms covered millions, but durable cost control remains elusive.

Read the full analysis →

#HealthEconomics #USHealthcare #PolicySolutions #SyenzaNews

Syenza TeamRead ›